《大行報告》富瑞下調中國海外(00688.HK)目標價至23.5元 評級「買入」
富瑞發表報告指,中國海外(00688.HK)今年上半年核心利潤按年跌20%至138億元人民幣,符合預期,收入按年跌14%,毛利率收窄至22.6%,中期每股派息為0.35元,派息率達2.2%。
該行指,相比8月份市場情緒低迷,管理層見到訪客走勢持續按月改善15%至20%,維持全年合約銷售目標達3,540億元人民幣。加上,公司擁有豐富的啟動渠道,該行認為公司會成為在第一、二線城市或推出支持措施的主要受益者。
富瑞表示,將中國海外在2023年至24年盈利預測上調3%至5%,並將其目標價由24.71元下調至23.5元,維持其評級為「買入」。(ca/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.